FI875724A0 - Av kalcium oberoende camp fosfodiesteras-inhibitordepressant. - Google Patents

Av kalcium oberoende camp fosfodiesteras-inhibitordepressant.

Info

Publication number: FI875724A0
Authority: FI; Finland
Prior art keywords: inhibitordepressant; oberoende; phosphodiesteras; camp; calcium
Prior art date: 1986-04-29

Application number

FI875724A

Other languages

English (en)

Other versions

FI875724L (fi

Inventor

Nicholas Alex Saccomano

Fredric James Vinick

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-29

Filing date

1987-12-28

Publication date

1987-12-28

1987-12-28 Application filed by Pfizer filed Critical Pfizer

1987-12-28 Publication of FI875724L publication Critical patent/FI875724L/fi

1987-12-28 Publication of FI875724A0 publication Critical patent/FI875724A0/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Curing Cements, Concrete, And Artificial Stone (AREA)
Steroid Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Polymerisation Methods In General (AREA)

FI875724A 1986-04-29 1987-12-28 Av kalcium oberoende camp fosfodiesteras-inhibitordepressant. FI875724A0 (fi)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1986/000958 WO1987006576A1 (en)	1986-04-29	1986-04-29	Calcium independent camp phosphodiesterase inhibitor antidepressant

Publications (2)

Publication Number	Publication Date
FI875724L FI875724L (fi)	1987-12-28
FI875724A0 true FI875724A0 (fi)	1987-12-28

Family

ID=22195483

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FI875660A FI94341C (fi)	1986-04-29	1987-12-22	Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi
FI875724A FI875724A0 (fi)	1986-04-29	1987-12-28	Av kalcium oberoende camp fosfodiesteras-inhibitordepressant.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FI875660A FI94341C (fi)	1986-04-29	1987-12-22	Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi

Country Status (28)

Country	Link
EP (1)	EP0247725B1 (fi)
JP (1)	JPH0645602B2 (fi)
KR (1)	KR900002064B1 (fi)
CN (1)	CN1018827B (fi)
AT (1)	ATE102189T1 (fi)
AU (1)	AU576448B2 (fi)
CA (1)	CA1331606C (fi)
CZ (1)	CZ280146B6 (fi)
DD (3)	DD280321A5 (fi)
DE (1)	DE3789164T2 (fi)
DK (1)	DK172033B1 (fi)
EG (1)	EG18239A (fi)
ES (1)	ES2061492T3 (fi)
FI (2)	FI94341C (fi)
HU (1)	HU215433B (fi)
IE (1)	IE63170B1 (fi)
IL (1)	IL82342A (fi)
IN (1)	IN167587B (fi)
MY (2)	MY102842A (fi)
NO (2)	NO875441D0 (fi)
NZ (1)	NZ220106A (fi)
PH (1)	PH25107A (fi)
PL (1)	PL153225B1 (fi)
PT (1)	PT84766B (fi)
SU (2)	SU1646488A3 (fi)
WO (1)	WO1987006576A1 (fi)
YU (4)	YU47969B (fi)
ZA (1)	ZA873014B (fi)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8610531D0 (en) *	1986-04-30	1986-06-04	Fbc Ltd	Herbicides
DE3823299A1 (de) *	1988-07-07	1990-01-11	Schering Ag	Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
WO1991007177A1 (en) *	1989-11-13	1991-05-30	Pfizer Inc.	Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
HU220962B1 (hu) *	1989-11-13	2002-07-29	Pfizer Inc.	Optikailag aktív 5-[3-(exo-biciklo[2.2.1]hept-2-il-oxi)-4-metoxi-fenil]-3,4,5,6-tetrahidropirimidin-2(1H)-on, enantiomere, valamint intermedierjeik
CA2088352A1 (en) *	1990-08-03	1992-02-04	Klaus M. Esser	Tnf inhibitors
US5124455A (en) *	1990-08-08	1992-06-23	American Home Products Corporation	Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
IE913855A1 (en) *	1990-11-06	1992-05-22	Smithkline Beecham Corp	Imidazolidinone compounds
US5547979A (en) *	1992-03-30	1996-08-20	Smithkline Beecham	TNF inhibition
US5395935A (en) *	1992-05-08	1995-03-07	Pfizer Inc.	Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
GB9212673D0 (en) *	1992-06-15	1992-07-29	Celltech Ltd	Chemical compounds
GB9222253D0 (en) *	1992-10-23	1992-12-09	Celltech Ltd	Chemical compounds
US5814651A (en) *	1992-12-02	1998-09-29	Pfizer Inc.	Catechol diethers as selective PDEIV inhibitors
PT672031E (pt) *	1992-12-02	2003-06-30	Pfizer	Dieteres de catecol como inibidores selectivos de pde iv
US5622977A (en) *	1992-12-23	1997-04-22	Celltech Therapeutics Limited	Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) *	1992-12-23	1993-02-17	Celltech Ltd	Chemical compounds
GB9304919D0 (en) *	1993-03-10	1993-04-28	Celltech Ltd	Chemical compounds
GB9304920D0 (en) *	1993-03-10	1993-04-28	Celltech Ltd	Chemical compounds
US5665754A (en) *	1993-09-20	1997-09-09	Glaxo Wellcome Inc.	Substituted pyrrolidines
ATE187447T1 (de) *	1993-11-26	1999-12-15	Pfizer	3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
US5502072A (en) *	1993-11-26	1996-03-26	Pfizer Inc.	Substituted oxindoles
WO1995017399A1 (en) *	1993-12-22	1995-06-29	Celltech Therapeutics Limited	Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
GB9326173D0 (en) *	1993-12-22	1994-02-23	Celltech Ltd	Chemical compounds and process
DK0749428T3 (da) *	1994-03-09	1998-11-16	Pfizer	Isooxazolinforbindelser som inhibitorer af TNF-frigivelse
CA2184914C (en) *	1994-03-09	2000-09-19	Victoria L. Cohan	Isoxazoline compounds as 5-lipoxygenase inhibitors
US5786354A (en) *	1994-06-21	1998-07-28	Celltech Therapeutics, Limited	Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en)	1994-06-21	2001-06-12	Celltech Therapeutics Limited	Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) *	1994-06-22	1994-08-10	Celltech Ltd	Chemical compounds
GB9412571D0 (en)	1994-06-22	1994-08-10	Celltech Ltd	Chemical compounds
GB9412672D0 (en) *	1994-06-23	1994-08-10	Celltech Ltd	Chemical compounds
US5922751A (en)	1994-06-24	1999-07-13	Euro-Celtique, S.A.	Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6022968A (en) *	1994-08-05	2000-02-08	Pfizer Inc	Processes for the synthesis of 5-(3-[exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydr opyrimidin-2(1H)-one
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9526245D0 (en) *	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9526246D0 (en) *	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
DE19617864A1 (de) *	1996-04-23	1997-10-30	Schering Ag	Neue chirale Phenyldihydrofuranone
GB9608435D0 (en) *	1996-04-24	1996-06-26	Celltech Therapeutics Ltd	Chemical compounds
US6294541B1 (en)	1996-06-06	2001-09-25	Euro-Celtique S.A.	Purine derivatives having phosphodiesterase IV inhibition activity
JP3192662B2 (ja)	1996-07-31	2001-07-30	日研化学株式会社	６―フェニルテトラヒドロ―１，３―オキサジン―２―オン誘導体及びそれを含む医薬組成物
EP0924204A4 (en)	1996-08-27	2002-10-23	Nikken Chemicals Co Ltd	2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
US5744473A (en) *	1996-09-16	1998-04-28	Euro-Celtique, S.A.	PDE IV inhibitors: "bis-compounds"
GB9622363D0 (en) *	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
GB9625184D0 (en) *	1996-12-04	1997-01-22	Celltech Therapeutics Ltd	Chemical compounds
AU5330698A (en) *	1996-12-23	1998-07-17	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) *	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
GB9713087D0 (en) *	1997-06-20	1997-08-27	Celltech Therapeutics Ltd	Chemical compounds
DE19882892T1 (de)	1997-12-12	2001-02-22	Euro Celtique Sa	Herstellung von 3-substituierten Adeninen und Imidazopyridinen
US6319928B1 (en)	1998-11-30	2001-11-20	Euro-Celtique, S.A.	Purine derivatives having phosphodiesterase IV inhibition activity
BR0011182A (pt)	1999-04-02	2003-06-10	Euro Celtique Sa	Derivados de purina tendo atividade inibidora de fosfodiesterase iv
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
GB9924862D0 (en)	1999-10-20	1999-12-22	Celltech Therapeutics Ltd	Chemical compounds
PL367130A1 (en)	2001-05-29	2005-02-21	Schering Aktiengesellschaft	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
KR100753017B1 (ko) *	2006-05-25	2007-08-30	한국화학연구원	7-(3,4-디알콕시페닐)-피라졸로[1,5-ａ]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
CA3089569C (en)	2007-06-04	2023-12-05	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en)	2008-07-16	2010-01-21	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP2011144169A (ja) *	2009-12-18	2011-07-28	Ishihara Sangyo Kaisha Ltd	イミダゾピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en)	2011-03-01	2018-08-29	Synergy Pharmaceuticals Inc.	Guanylate cyclase c agonists
CN102731411B (zh) *	2012-06-15	2014-10-22	湖南大学	4-烷基-6-芳基-3,4-二氢嘧啶-2-硫酮的制备及其作为抗抑郁药物的应用
US9545446B2 (en)	2013-02-25	2017-01-17	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
ES2981866T3 (es)	2013-06-05	2024-10-10	Bausch Health Ireland Ltd	Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos
EP3884935B1 (en)	2013-08-09	2023-06-14	Ardelyx, Inc.	Compounds and methods for inhibiting phosphate transport
JP2022533251A (ja)	2019-05-21	2022-07-21	アルデリックス，インコーポレイテッド	患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1451154A (fr) *	1959-06-22	1966-01-07	Guy Hue Lab	Nouveaux dérivés pyrazoliques et leur procédé de préparation
NL136620C (fi) *	1963-04-30
US3923833A (en) *	1968-05-01	1975-12-02	Hoffmann La Roche	N-{8 (1-cyano-2-phenyl)ethyl{9 carbamates
BE759176A (fr) *	1969-11-20	1971-05-19	Sandoz Sa	Derives de la pyrimidine, leur preparation et medicaments contenant cesderives
US3636039A (en) *	1970-02-24	1972-01-18	Hoffmann La Roche	Substituted benzylimidazolidinones
DE2413935A1 (de) *	1974-03-20	1975-10-16	Schering Ag	4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) *	1974-03-20	1980-03-18	Schering Aktiengesellschaft	4-(Polyalkoxy phenyl)-2-pyrrolidones
IE40911B1 (en) *	1974-04-11	1979-09-12	Schering Ag	Imidazole derivatives and process for their manufacture
DE2541855A1 (de) *	1975-09-18	1977-03-31	Schering Ag	4-(polyalkoxy-phenyl)-2-pyrrolidone ii
SU888821A3 (ru) *	1976-12-03	1981-12-07	Шеринг Аг (Инофирма)	Способ получени 5-(замещенный фенил)-оксазолидинонов или их серусодержащих аналогов
HU179019B (en) *	1978-11-01	1982-08-28	Gyogyszekutato Intezet	Process for preparing 4-//3,4-dialkoxy-phenyl/-alkyl/- 2imidazolidinone derivatives
US4261995A (en) *	1979-08-31	1981-04-14	Syntex (U.S.A.) Inc.	4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives
DE3130633A1 (de) *	1981-08-01	1983-02-17	Basf Ag, 6700 Ludwigshafen	7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3315797A1 (de) *	1983-04-30	1984-10-31	Beiersdorf Ag, 2000 Hamburg	Substituierte phenyl-2-(1h)-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
JPS6019789A (ja) *	1983-07-12	1985-01-31	Kyorin Pharmaceut Co Ltd	イミダゾ〔１，５−ａ〕ピリミジン誘導体

1986
- 1986-04-29 HU HU111/86A patent/HU215433B/hu not_active IP Right Cessation
- 1986-04-29 WO PCT/US1986/000958 patent/WO1987006576A1/en active IP Right Grant
1987
- 1987-02-11 IN IN107/DEL/87A patent/IN167587B/en unknown
- 1987-02-16 MY MYPI87000152A patent/MY102842A/en unknown
- 1987-03-22 EG EG170/87A patent/EG18239A/xx active
- 1987-04-22 IE IE103687A patent/IE63170B1/en not_active IP Right Cessation
- 1987-04-23 EP EP87303563A patent/EP0247725B1/en not_active Expired - Lifetime
- 1987-04-23 ES ES87303563T patent/ES2061492T3/es not_active Expired - Lifetime
- 1987-04-23 DE DE3789164T patent/DE3789164T2/de not_active Expired - Fee Related
- 1987-04-23 AT AT87303563T patent/ATE102189T1/de not_active IP Right Cessation
- 1987-04-27 CZ CS872989A patent/CZ280146B6/cs not_active IP Right Cessation
- 1987-04-27 CA CA000535594A patent/CA1331606C/en not_active Expired - Fee Related
- 1987-04-27 IL IL82342A patent/IL82342A/xx not_active IP Right Cessation
- 1987-04-27 PL PL1987265397A patent/PL153225B1/pl unknown
- 1987-04-27 PT PT84766A patent/PT84766B/pt unknown
- 1987-04-27 JP JP62104168A patent/JPH0645602B2/ja not_active Expired - Fee Related
- 1987-04-27 NZ NZ220106A patent/NZ220106A/xx unknown
- 1987-04-28 PH PH35193A patent/PH25107A/en unknown
- 1987-04-28 DD DD87326852A patent/DD280321A5/de not_active IP Right Cessation
- 1987-04-28 DK DK215087A patent/DK172033B1/da not_active IP Right Cessation
- 1987-04-28 KR KR1019870004068A patent/KR900002064B1/ko not_active Expired
- 1987-04-28 DD DD87302222A patent/DD273773A5/de not_active IP Right Cessation
- 1987-04-28 AU AU72142/87A patent/AU576448B2/en not_active Ceased
- 1987-04-28 YU YU77387A patent/YU47969B/sh unknown
- 1987-04-28 ZA ZA873014A patent/ZA873014B/xx unknown
- 1987-04-28 CN CN87103225A patent/CN1018827B/zh not_active Expired
- 1987-04-28 DD DD87326854A patent/DD280319A5/de not_active IP Right Cessation
- 1987-12-22 FI FI875660A patent/FI94341C/fi not_active IP Right Cessation
- 1987-12-28 NO NO1987875441A patent/NO875441D0/no unknown
- 1987-12-28 NO NO87875440A patent/NO173138C/no not_active IP Right Cessation
- 1987-12-28 FI FI875724A patent/FI875724A0/fi not_active Application Discontinuation
1988
- 1988-06-14 YU YU115788A patent/YU46916B/sh unknown
- 1988-06-14 YU YU115688A patent/YU47195B/sh unknown
- 1988-06-14 YU YU115588A patent/YU46915B/sh unknown
- 1988-12-12 SU SU884613064A patent/SU1646488A3/ru active
- 1988-12-22 SU SU884613133A patent/SU1653542A3/ru active
1992
- 1992-02-24 MY MYPI92000292A patent/MY106638A/en unknown

Also Published As

Publication number	Publication date
ZA873014B (en)	1988-12-28
NO875440L (no)	1987-12-28
PT84766A (en)	1987-05-01
PL153225B1 (en)	1991-03-29
DK215087D0 (da)	1987-04-28
PT84766B (pt)	1989-12-29
FI875660A0 (fi)	1987-12-22
NO173138B (no)	1993-07-26
SU1646488A3 (ru)	1991-04-30
CZ280146B6 (cs)	1995-11-15
DK172033B1 (da)	1997-09-22
KR900002064B1 (ko)	1990-03-31
KR870010009A (ko)	1987-11-30
DD273773A5 (de)	1989-11-29
DE3789164D1 (de)	1994-04-07
IE871036L (en)	1987-10-29
YU47969B (sh)	1996-08-13
ATE102189T1 (de)	1994-03-15
YU115788A (en)	1988-10-31
IL82342A (en)	1992-03-29
CZ298987A3 (en)	1995-05-17
YU115688A (en)	1988-10-31
FI94341C (fi)	1995-08-25
DK215087A (da)	1987-10-30
NO173138C (no)	1993-11-03
IN167587B (fi)	1990-11-17
EP0247725B1 (en)	1994-03-02
PH25107A (en)	1991-02-19
SU1653542A3 (ru)	1991-05-30
EG18239A (en)	1992-10-30
EP0247725A3 (en)	1990-01-17
JPS62281864A (ja)	1987-12-07
CN1018827B (zh)	1992-10-28
MY106638A (en)	1995-07-31
CA1331606C (en)	1994-08-23
HUT63150A (en)	1993-07-28
NO875441D0 (no)	1987-12-28
FI875724L (fi)	1987-12-28
DE3789164T2 (de)	1994-06-09
JPH0645602B2 (ja)	1994-06-15
YU46915B (sh)	1994-06-24
YU77387A (en)	1988-10-31
MY102842A (en)	1993-03-31
DD280321A5 (de)	1990-07-04
NO875440D0 (no)	1987-12-28
YU115588A (en)	1988-10-31
NZ220106A (en)	1991-08-27
WO1987006576A1 (en)	1987-11-05
AU7214287A (en)	1987-12-10
FI94341B (fi)	1995-05-15
ES2061492T3 (es)	1994-12-16
IE63170B1 (en)	1995-03-22
EP0247725A2 (en)	1987-12-02
FI875660L (fi)	1987-12-22
PL265397A1 (en)	1988-07-21
CN87103225A (zh)	1987-11-11
AU576448B2 (en)	1988-08-25
YU46916B (sh)	1994-06-24
YU47195B (sh)	1995-01-31
DD280319A5 (de)	1990-07-04
HU215433B (hu)	2000-05-28

Publication	Publication Date	Title
FI875724A0 (fi)	1987-12-28	Av kalcium oberoende camp fosfodiesteras-inhibitordepressant.
NL971014I2 (nl)	1998-01-05	Heterocyclische verbindingen.
ATE172201T1 (de)	1998-10-15	Morphinan-derivate und medizinische verwendung
ATE86623T1 (de)	1993-03-15	8-azabicyclo(3,2,1>octan- und 9azabicyclo(3,3,1>nonanderivate.
FI911980A0 (fi)	1991-04-24	N-(3-fluor-2-fosfonylmetoxipropyl) -derivat av heterocykliska purin- och pyrimidinbaser, deras framstaellning och anvaendning.
DK465380A (da)	1981-05-03	Fremgangsmaade til fremstilling af azepinderivater
DE68926810D1 (de)	1996-08-14	Benzoxazepinon-Verfahren
SE7606424L (sv)	1976-12-11	Substituerade bensamider
FI863701A0 (fi)	1986-09-12	Propanolderivat.
SU1624959A1 (ru)	2000-11-27	5-(β-П-МЕТОКСИФЕНИЛ-β-ОКСИЭТИЛ)-2-МЕТИЛТИО-1-МЕТИЛ-4,5,6,7-ТЕТРАГИДРОИ МИДАЗО[4,5-C]ПИРИДИНА ДИГИДРОХЛОРИД, ОБЛАДАЮЩИЙ ГИПОТЕНЗИВНЫМ, АНТИГИПЕРТЕНЗИВНЫМ, СПАЗМОЛИТИЧЕСКИМ И СЕДАТИВНЫМ ДЕЙСТВИЕМ

Legal Events

Date	Code	Title	Description
2004-08-31	FA	Application withdrawn [patent]	Owner name: PFIZER INC.